Drug intelligence / Profile preview

dermatophagoides pteronyssinus + dermatophagoides farinae

Development stage
Unknown
Lead developer
Jubilant HollisterStier
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intradermal, Percutaneous, Subcutaneous
01

Overview

Dermatophagoides pteronyssinus + dermatophagoides farinae is a standardized **allergen extract combination** comprising equal parts extracts from the European house dust mite and the American house dust mite, marketed by Jubilant HollisterStier as **Standardized Mite Mix**. It is an FDA-licensed biologic allergenic product used both as a **diagnostic skin-test reagent** for patients with a clinical history suggestive of dust mite allergy and as **allergen immunotherapy** to mitigate mite-induced allergic asthma, allergic rhinitis, and allergic conjunctivitis in sensitized patients. Mechanistically, it delivers relevant dust-mite allergen proteins that bind allergen-specific IgE on mast cells and basophils for diagnostic reactivity, while repeated therapeutic administration is intended to induce immune tolerance and modulate the pathogenic IgE-mediated allergic response, although the full immunologic mechanism of allergen immunotherapy is not completely defined. The product is administered via percutaneous, intradermal, or subcutaneous routes depending on use and is marketed under FDA BLAs 103870 and 103871.

Brand names
Standardized Mite Mix
Other names
standardized mite mixture extractdermatophagoides pteronyssinus + dermatophagoides farinaemite mix allergenic extractstandardized mite extract mixture
02

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on dermatophagoides pteronyssinus + dermatophagoides farinae.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dermatophagoides pteronyssinus + dermatophagoides farinae.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call